2020 2019 Reported Operational (1) Currency CONSUMER HEALTH SEGMENT (2,3) BABY CARE US 92 $ 87 6.7% 6.7% - Intl 269 307 -12.4% -8.2% -4.2% WW 361 394 -8.2% -4.9% -3.3% SKIN HEALTH / BEAUTY(4) US 659 588 12.1% 12.1% - Intl 458 502 -8.8% -6.5% -2.3% WW 1,117 1,090 2.5% 3.5% -1.0% ORAL CARE US 176 151 16.2% 16.2% - Intl 219 216 1.5% 5.3% -3.8% WW 395 367 7.6% 9.8% -2.2% OTC US 689 507 35.9% 35.9% - Intl 659 580 13.7% 17.0% -3.3% WW 1,348 1,087 24.1% 25.8% -1.7% WOMEN'S HEALTH US 4 3 32.0% 32.0% - Intl 228 222 2.5% 8.9% -6.4% WW 232 225 2.9% 9.2% -6.3% WOUND CARE / OTHER US 119 102 17.0% 17.0% - Intl 52 53 -1.2% 1.9% -3.1% WW 171 155 10.7% 11.8% -1.1% TOTAL CONSUMER HEALTH US 1,740 1,438 21.0% 21.0% - Intl 1,885 1,880 0.3% 3.9% -3.6% WW 3,625 $ 3,318 9.2% 11.3% -2.1% See footnotes at end of schedule REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER % Change -- 1 of 6 -- 2020 2019 Reported Operational (1) Currency PHARMACEUTICAL SEGMENT (2) IMMUNOLOGY US 2,410 $ 2,163 11.4% 11.4% - Intl 1,228 1,088 12.8% 16.3% -3.5% WW 3,638 3,251 11.9% 13.1% -1.2% REMICADE US 625 774 -19.3% -19.3% - US Exports (5) 110 76 44.3% 44.3% - Intl 256 252 1.5% 5.2% -3.7% WW 990 1,102 -10.2% -9.3% -0.9% SIMPONI / SIMPONI ARIA US 272 263 3.4% 3.4% - Intl 258 261 -1.2% 2.6% -3.8% WW 529 524 1.1% 3.0% -1.9% STELARA US 1,217 882 37.9% 37.9% - Intl 603 523 15.2% 18.3% -3.1% WW 1,819 1,405 29.5% 30.6% -1.1% TREMFYA US 187 168 11.5% 11.5% - Intl 109 49 * * * WW 296 217 36.4% 37.3% -0.9% OTHER IMMUNOLOGY US - - - - - Intl 3 3 -6.9% -5.6% -1.3% WW 3 3 -6.9% -5.6% -1.3% INFECTIOUS DISEASES US 436 357 22.3% 22.3% - Intl 483 489 -1.2% 2.7% -3.9% WW 920 846 8.7% 11.0% -2.3% EDURANT / rilpivirine US 12 12 0.6% 0.6% - Intl 212 199 6.4% 9.2% -2.8% WW 224 211 6.1% 8.7% -2.6% PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA US 396 315 25.5% 25.5% - Intl 184 208 -11.6% -6.4% -5.2% WW 579 523 10.8% 12.8% -2.0% OTHER INFECTIOUS DISEASES US 29 30 -3.4% -3.4% - Intl 87 82 6.7% 10.2% -3.5% WW 116 112 4.0% 6.6% -2.6% See footnotes at end of schedule REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER % Change -- 2 of 6 -- 2020 2019 Reported Operational (1) Currency NEUROSCIENCE US 748 723 3.3% 3.3% - Intl 910 905 0.5% 3.0% -2.5% WW 1,658 1,629 1.8% 3.1% -1.3% CONCERTA / Methylphenidate US 52 97 -46.1% -46.1% - Intl 118 116 1.5% 3.6% -2.1% WW 171 214 -20.1% -19.0% -1.1% INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA US 544 483 12.6% 12.6% - Intl 339 307 10.3% 13.2% -2.9% WW 883 790 11.7% 12.9% -1.2% RISPERDAL CONSTA US 76 77 -0.3% -0.3% - Intl 94 102 -8.7% -5.9% -2.8% WW 170 179 -5.1% -3.5% -1.6% OTHER NEUROSCIENCE US 75 66 12.5% 12.5% - Intl 360 379 -5.1% -3.1% -2.0% WW 435 446 -2.5% -0.8% -1.7% ONCOLOGY US 1,175 962 22.1% 22.1% - Intl 1,839 1,556 18.2% 21.7% -3.5% WW 3,013 2,518 19.7% 21.8% -2.1% DARZALEX US 463 352 31.8% 31.8% - Intl 474 277 70.9% 76.8% -5.9% WW 937 629 49.0% 51.6% -2.6% ERLEADA (6) US 119 58 * * - Intl 24 3 * * * WW 143 61 * * * IMBRUVICA US 432 349 23.9% 23.9% - Intl 599 435 37.8% 42.3% -4.5% WW 1,031 784 31.6% 34.1% -2.5% VELCADE US - - - - - Intl 108 263 -59.0% -58.2% -0.8% WW 108 263 -59.0% -58.2% -0.8% ZYTIGA / abiraterone acetate US 139 185 -25.2% -25.2% - Intl 552 494 11.7% 14.3% -2.6% WW 690 679 1.6% 3.5% -1.9% OTHER ONCOLOGY(6) US 22 18 20.1% 20.1% - Intl 82 84 -2.7% 0.6% -3.3% WW 104 102 1.3% 4.1% -2.8% See footnotes at end of schedule REPORTED SALES vs. PRIOR PERIOD ($MM) % Change FIRST QUARTER -- 3 of 6 -- 2020 2019 Reported Operational (1) Currency PULMONARY HYPERTENSION US 486 430 13.0% 13.0% - Intl 260 226 14.9% 17.8% -2.9% WW 745 656 13.7% 14.7% -1.0% OPSUMIT US 229 172 33.0% 33.0% - Intl 160 133 20.2% 23.3% -3.1% WW 389 306 27.4% 28.8% -1.4% UPTRAVI US 212 176 20.7% 20.7% - Intl 38 22 70.2% 75.0% -4.8% WW 250 198 26.2% 26.8% -0.6% OTHER PULMONARY HYPERTENSION(6) US 44 82 -45.9% -45.9% - Intl 62 71 -12.4% -10.7% -1.7% WW 106 152 -30.4% -29.6% -0.8% CARDIOVASCULAR / METABOLISM / OTHER US 806 947 -14.9% -14.9% - Intl 354 398 -11.0% -8.7% -2.3% WW 1,160 1,345 -13.8% -13.1% -0.7% XARELTO US 527 542 -2.7% -2.7% - Intl - - - - - WW 527 542 -2.7% -2.7% - INVOKANA / INVOKAMET US 117 154 -23.6% -23.6% - Intl 58 49 18.6% 20.9% -2.3% WW 175 202 -13.5% -12.9% -0.6% PROCRIT / EPREX US 76 148 -48.5% -48.5% - Intl 79 78 0.4% 1.9% -1.5% WW 155 226 -31.6% -31.0% -0.6% OTHER US 85 104 -18.0% -18.0% - Intl 217 271 -19.7% -17.1% -2.6% WW 302 374 -19.2% -17.4% -1.8% TOTAL PHARMACEUTICAL US 6,061 5,582 8.6% 8.6% - Intl 5,073 4,662 8.8% 12.0% -3.2% WW 11,134 $ 10,244 8.7% 10.1% -1.4% See footnotes at end of schedule REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER % Change -- 4 of 6 -- 2020 2019 Reported Operational (1) Currency MEDICAL DEVICES SEGMENT (2) INTERVENTIONAL SOLUTIONS US 365 343 6.6% 6.6% - Intl 362 389 -6.9% -5.1% -1.8% WW 727 732 -0.6% 0.4% -1.0% ORTHOPAEDICS US 1,250 1,318 -5.2% -5.2% - Intl 788 885 -11.0% -8.5% -2.5% WW 2,038 2,204 -7.5% -6.5% -1.0% HIPS US 206 213 -3.6% -3.6% - Intl 132 148 -11.2% -8.4% -2.8% WW 337 361 -6.7% -5.6% -1.1% KNEES US 214 223 -4.2% -4.2% - Intl 130 146 -11.4% -8.9% -2.5% WW 343 369 -7.0% -6.1% -0.9% TRAUMA US 407 417 -2.3% -2.3% - Intl 247 268 -8.0% -5.3% -2.7% WW 654 685 -4.5% -3.5% -1.0% SPINE, SPORTS & OTHER(7) US 423 465 -8.9% -8.9% - Intl 280 323 -13.3% -11.1% -2.2% WW 703 788 -10.7% -9.8% -0.9% SURGERY US 844 1,001 -15.7% -15.7% - Intl 1,257 1,394 -9.8% -6.7% -3.1% WW 2,100 2,395 -12.3% -10.5% -1.8% ADVANCED US 381 404 -5.7% -5.7% - Intl 567 576 -1.6% 1.6% -3.2% WW 948 980 -3.3% -1.4% -1.9% GENERAL(6) US 463 597 -22.5% -22.5% - Intl 690 818 -15.7% -12.6% -3.1% WW 1,153 1,414 -18.5% -16.8% -1.7% VISION US 439 446 -1.6% -1.6% - Intl 628 682 -8.0% -6.4% -1.6% WW 1,067 1,129 -5.5% -4.5% -1.0% CONTACT LENSES / OTHER US 346 321 7.7% 7.7% - Intl 467 502 -7.0% -5.4% -1.6% WW 814 824 -1.3% -0.3% -1.0% SURGICAL US 93 125 -25.5% -25.5% - Intl 160 180 -11.0% -9.2% -1.8% WW 253 305 -16.9% -15.9% -1.0% TOTAL MEDICAL DEVICES US 2,898 3,109 -6.8% -6.8% - Intl 3,034 3,350 -9.4% -6.9% -2.5% WW 5,932 $ 6,459 -8.2% -6.9% -1.3% * Percentage greater than 100% or not meaningful (1) Operational growth excludes the effect of translational currency (5) Reported as U.S. sales (2) Unaudited (6) Refer to supplemental schedule (3) Previously referred to as Consumer (7) Previously referred to as Spine & Other (4) Previously referred to as Beauty REPORTED SALES vs. PRIOR PERIOD ($MM) FIRST QUARTER Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures, and therefore, may not recalculate precisely. % Change -- 5 of 6 -- Full Year Q1 Q2 Q3 Q4 Full Year PHARMACEUTICAL SEGMENT (1) ERLEADA(2) US 124 58 62 74 103 297 Intl - 3 7 12 13 35 WW 124 61 69 86 116 332 OTHER ONCOLOGY(2) US 104 18 16 17 19 70 Intl 362 84 85 83 84 336 WW 466 102 101 100 104 407 Full Year Q1 Q2 Q3 Q4 Full Year Pulmonary Hypertension OTHER PAH(3) US 353 82 61 36 26 205 Intl 342 71 78 61 62 272 WW 695 152 140 96 88 476 Full Year Q1 Q2 Q3 Q4 Full Year MEDICAL DEVICES SEGMENT (1) GENERAL SURGERY(4) US 2,468 597 530 531 534 2,192 Intl 3,431 818 794 769 834 3,215 WW 5,899 1,414 1,325 1,301 1,366 5,406 Note: Columns and rows within tables may not add due to rounding. (1) Unaudited (2) ERLEADA was previously included in Other Oncology (3) Other PAH is inclusive of TRACLEER, which was previously disclosed separately (4) General Surgery is inclusive of Specialty Surgery, which was previously disclosed separately Supplemental Schedule Prior quarter amounts have been reclassified to conform to current quarter product disclosure ($MM) 2018 2019 2018 2019 2019 2019 2019 2018 2019 -- 6 of 6 --